Lasmiditan

NERVOUS SYSTEM

Key facts

Lasmiditan is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2019. DrugCentral lists 9 molecular targets, including HTR1F, HTR1E and TMEM97. Recorded indications include Migraine.

• Approval status: ofm (first approved 2019 by the FDA).
• Molecular targets: HTR1F, HTR1E, TMEM97 and DRD5 (9 listed in DrugCentral).
• Indications: Migraine.
• ATC code: N02CC08 (Selective serotonin (5HT1) agonists).
• Molecular formula: C19H18F3N3O2; molecular weight 377.37 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Migraine

Mechanism & targets

Molecular targets (9)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 1F	HTR1F	agonist	Ki 8.65
5-hydroxytryptamine receptor 1E	HTR1E	unknown	Ki 6.90
Transmembrane protein 97	TMEM97	unknown	Ki 6.74
D(1B) dopamine receptor	DRD5	unknown	Ki 6.60
Kappa-type opioid receptor	OPRK1	unknown	Ki 6.45
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 6.20
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 6.06
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 5.50
5-hydroxytryptamine receptor 7	HTR7	unknown	Ki 5.27

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-08-17	EMA	—	Eli Lilly Nederland B.V.
2022-01-20	PMDA	—	ELI LILLY JAPAN K.K.
2019-11-10	FDA	—	ELI LILLY AND CO

ATC classification

ATC code	Therapeutic hierarchy
N02CC08	NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Selective serotonin (5HT1) agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Dizziness	340.6
Feeling abnormal	237.5
Sedation	216.9
Somnolence	144.3
Euphoric mood	76.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Lasmiditan is on its molecule page.

• Molecular formula: C₁₉H₁₈F₃N₃O₂
• Molecular weight: 377.37 g/mol
• CAS number: 439239-90-4
• InChIKey: XEDHVZKDSYZQBF-UHFFFAOYSA-N
• PubChem CID: 11610526

CN1CCC(CC1)C(=O)C1=NC(NC(=O)C2=C(F)C=C(F)C=C2F)=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lasmiditan used for?

DrugCentral lists the following indications for Lasmiditan: Migraine.

How does Lasmiditan work?

Its molecular targets in DrugCentral include HTR1F (agonist), HTR1E, TMEM97 and DRD5.

When was Lasmiditan first approved?

Lasmiditan was first approved by the FDA in 2019.

What is the chemical formula of Lasmiditan?

Lasmiditan has the molecular formula C19H18F3N3O2 and a molecular weight of 377.37 g/mol.

Sources

• DrugCentral drug card 5351 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3039520 — compound record and bioactivity
• PubChem CID 11610526 — chemical identifiers
• DrugBank DB11732 — drug record
• FDA UNII 760I9WM792 — substance identity
• DailyMed: FDA labels for Lasmiditan — current prescribing information (label search)
• UniProt P30939 (HTR1F) — target protein
• UniProt P28566 (HTR1E) — target protein
• UniProt Q5BJF2 (TMEM97) — target protein
• UniProt P21918 (DRD5) — target protein
• UniProt P41145 (OPRK1) — target protein
• UniProt P08912 (CHRM5) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.